Syngene International Ltd
NSE:SYNGENE

Watchlist Manager
Syngene International Ltd Logo
Syngene International Ltd
NSE:SYNGENE
Watchlist
Price: 847.2 INR 0.55%
Market Cap: 340B INR
Have any thoughts about
Syngene International Ltd?
Write Note

Syngene International Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Syngene International Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Syngene International Ltd
NSE:SYNGENE
Gross Profit
â‚ą25.4B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Gross Profit
â‚ą48.9B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Gross Profit
â‚ą20.6B
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Vimta Labs Ltd
NSE:VIMTALABS
Gross Profit
â‚ą2.4B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
12%
I
Innova Captab Ltd
NSE:INNOVACAP
Gross Profit
â‚ą3.3B
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Syngene International Ltd
Glance View

Market Cap
339.9B INR
Industry
Life Sciences Tools & Services

In the bustling landscape of the global pharmaceutical industry, Syngene International Ltd. stands out as a beacon of scientific innovation and strategic acumen. Founded in 1993, this Bangalore-based contract research and manufacturing organization (CRMO) has carved a niche by seamlessly blending cutting-edge research with commercial savvy. Syngene offers integrated services spanning the entire drug discovery and development continuum, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. By providing end-to-end solutions, from target identification and discovery chemistry to pre-clinical and clinical development and up to commercial manufacturing, Syngene ensures that its clients can focus on their core competencies, thus accelerating their journey from lab to market. Syngene's revenue model thrives on fostering long-term partnerships with global giants such as Bristol-Myers Squibb, Amgen, and Baxter, who rely on the company's deep scientific expertise and robust infrastructure. By offering bespoke solutions that address specific client needs, Syngene generates income through flexible, multi-year contracts and milestone payments at various stages of the drug development cycle. This approach not only ensures a steady revenue stream but also strengthens Syngene's reputation as a trusted partner in scientific innovation. With their state-of-the-art facilities and a team of world-class scientists, Syngene effectively marries scientific curiosity with business excellence, driving the future of health sciences and securing its position as a pivotal player in the CRMO field.

SYNGENE Intrinsic Value
610.52 INR
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Syngene International Ltd's Gross Profit?
Gross Profit
25.4B INR

Based on the financial report for Sep 30, 2024, Syngene International Ltd's Gross Profit amounts to 25.4B INR.

What is Syngene International Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
13%

Over the last year, the Gross Profit growth was 1%. The average annual Gross Profit growth rates for Syngene International Ltd have been 13% over the past three years , 13% over the past five years .

Back to Top